Skip to main content

Larimar Therapeutics, Inc.

corporate_fare Company Profile

Larimar Therapeutics, Inc.

LRMR·NASDAQ·Life Sciences·CIK 0001374690

We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide ("CPP") technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich's ataxia ("FA"). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Currently, there are no treatment options that address the core deficit of FA, low levels of FXN. Nomlabofusp represents the first potential therapy designed to systemically increase FXN levels in patients with FA. We believe that our CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, also has the potential to enable the treatment of other rare and orphan diseases. We intend to use our proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity. Since our inception, we have devoted substantially all of our resources to developing nomlabofusp, building our intellectual property portfolio, developing third-party manufacturing capabilities, business planning, raising capital, and providing general and administrative support for such operations. As of December 31, 2025, we had cash, cash equivalents, and marketable securities of $136.9 million. Nomlabofusp has Orphan Drug Designation, Fast Track Designation, Pediatric Rare Disease Designation and Breakthrough Therapy Designation from the FDA. It has also been granted Orphan Drug Designation and access to the European Medicines Agency's ("EMA's") Priority Medicines Program ("PRIME") scheme in the European Union (the "EU"). We have also received access in the United Kingdom (the "UK") to the Medicines and Healthcare Regulatory Agency's ("MHRA") Innovative Licensing and Access Pathway ("ILAP").

Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for LRMR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for LRMR spans 10-Q, 8-K, 4, DEF 14A.

Recent high-impact activity:

  • Larimar 10-Q: $93.5M Nine-Month Loss, $128.7M Cash Into Late Q2 2027, New Fill/Finish Form 483
  • Larimar Posts $31.1M Q3 Loss, Cash to Late Q2 2027 Ahead of BLA Acceptance
  • Larimar CEO Ben-Maimon Buys 18,050 Shares for ~$50K, Fourth Insider Buy This Week
  • Larimar Completes Rolling BLA for Nomlabofusp; $128.7M Cash Runs to Late Q2 2027
  • Larimar Q2 2026: Going Concern Warning Despite BLA Progress — Cash Runway Only Into Q3 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$165.67M
Op. Cash Flow
-$113.2M
Free Cash Flow
-$113.29M
Operating Income
-$172.5M
Cash & Equivalents
$85.41M
Debt / Equity
0.00×
Shares Outstanding
83.09M sh
Source: 10-K · filed 2026-03-19 · accession 0001193125-26-115878

Short Interest & Short Volume

8.25 days to cover

FINRA reported short interest of 10,538,346 shares in LRMR as of the October 30, 2026 settlement, a 28.1% decrease from the prior period — about 8.3 days to cover at its recent average daily volume. On November 20, 2026, 54.4% of LRMR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,538,346 shares as of October 30, 2026
Change vs prior period▼ 28.1%
Days to cover8.25 at avg daily volume of 1,277,756
Daily short volume (FINRA facilities)54.4% of 567,011 shares on November 20, 2026
5-day average short volume53.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with L →
$2.88 -8.36% today
52-week range · as of 2026-11-16 $1.92 – $6.42
Market cap
$328.55M
Volume
1.7M (1.1× avg)
3-mo avg 1.6M
Live data · 2026-11-22 05:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LRMR - Latest Insights

LRMR
Nov 16, 2026, 8:32 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.00
Real-time Price: $2.88 info
Change: -$0.1225 (-4%) info
Market Cap: $328.553M info
LRMR
Nov 16, 2026, 7:17 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.90
Real-time Price: $2.88 info
Change: -$0.0225 (-0.78%) info
Market Cap: $328.553M info
LRMR
Nov 12, 2026, 6:02 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $2.73
Real-time Price: $2.88 info
Change: +$0.1475 (+5%) info
Market Cap: $328.553M info
LRMR
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.53
Real-time Price: $2.88 info
Change: +$0.3475 (+14%) info
Market Cap: $328.553M info
LRMR
Aug 04, 2026, 7:12 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.95
Real-time Price: $2.88 info
Change: -$1.07 (-27%) info
Market Cap: $328.553M info
LRMR
Aug 04, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.80
Real-time Price: $2.88 info
Change: -$0.9225 (-24%) info
Market Cap: $328.553M info
LRMR
Aug 04, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.81
Real-time Price: $2.88 info
Change: -$0.937 (-25%) info
Market Cap: $328.553M info
LRMR
Jun 29, 2026, 6:33 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.81
Real-time Price: $2.88 info
Change: -$0.9325 (-24%) info
Market Cap: $328.553M info
LRMR
May 19, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.32
Real-time Price: $2.88 info
Change: -$0.4425 (-13%) info
Market Cap: $328.553M info
LRMR
May 14, 2026, 4:18 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.94
Real-time Price: $2.88 info
Change: -$1.06 (-27%) info
Market Cap: $328.553M info
LRMR
May 14, 2026, 7:08 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $4.10
Real-time Price: $2.88 info
Change: -$1.22 (-30%) info
Market Cap: $328.553M info
LRMR
May 14, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.10
Real-time Price: $2.88 info
Change: -$1.22 (-30%) info
Market Cap: $328.553M info
LRMR
Apr 20, 2026, 4:06 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $4.81
Real-time Price: $2.88 info
Change: -$1.93 (-40%) info
Market Cap: $328.553M info
LRMR
Apr 10, 2026, 4:09 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $4.85
Real-time Price: $2.88 info
Change: -$1.97 (-41%) info
Market Cap: $328.553M info
LRMR
Mar 19, 2026, 3:41 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $4.52
Real-time Price: $2.88 info
Change: -$1.64 (-36%) info
Market Cap: $328.553M info
LRMR
Mar 19, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.31
Real-time Price: $2.88 info
Change: -$1.43 (-33%) info
Market Cap: $328.553M info
LRMR
Mar 19, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $4.31
Real-time Price: $2.88 info
Change: -$1.43 (-33%) info
Market Cap: $328.553M info
LRMR
Mar 09, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $5.77
Real-time Price: $2.88 info
Change: -$2.89 (-50%) info
Market Cap: $328.553M info
LRMR
Mar 09, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.93
Real-time Price: $2.88 info
Change: -$3.06 (-52%) info
Market Cap: $328.553M info
LRMR
Mar 02, 2026, 7:46 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $5.48
Real-time Price: $2.88 info
Change: -$2.60 (-47%) info
Market Cap: $328.553M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets